[ad_1]
Shots:
- J&J has reported longer follow-up results from Cohorts D & E of the P-Ib/II (OrigAMI-1) trial assessing Rybrevant (amivantamab-vmjw; IV) ± FOLFOX/FOLFIRI in pts with RAS/BRAF wild-type mCRC
- At mFU of 16mos., Rybrevant + FOLFOX (n=20) or FOLFIRI (n=23) achieved a cORR of 51%, with early responses & median time to first response of 8.3wks., mDoR of 9.3mos., mPFS of 9.2mos., & mOS was not estimable. In pts with liver metastases (n=30), ORR was 57% with an mPFS of 11.3mos.
- In 1L pts, ORR was 73% with mDOR not reached at time of data cutoff; 4/11 pts proceeded to curative-intent surgery. In 2L (n=32), ORR was 44%, mDOR was 7.4mos., with >33% pts on therapy for >1yr. & 3 pts remained on amivantamab for >2yrs.
Ref: J&J | Image: J&J | Press Release
Related News: Johnson & Johnson Reports Topline P-IIb (JASMINE) Trial Data on Imaavy (Nipocalimab) for Systemic Lupus Erythematosus (SLE)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
[ad_2]
Source link
